You just read:

Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead Drug Candidate, Bryostatin-1, for the Treatment of Advanced Alzheimer's Disease

News provided by

Neurotrope, Inc.

Aug 15, 2016, 08:30 ET